Immunotherapy for NSCLC: A Pharmacist’s Guide

The treatment landscape for advanced non-small cell lung cancer (NSCLC) is rapidly evolving, particularly with the increasing role of immunotherapy. Pharmacists are playing an increasingly vital role in navigating this complexity, ensuring patients receive safe and effective care.

NSCLC remains a significant health challenge, with a poor prognosis for many patients. As of July 2023, the most prevalent type of lung cancer, accounting for approximately 85% of cases, treatment strategies have expanded beyond traditional methods like surgery, chemotherapy, and radiation therapy to include targeted therapies and, crucially, immunotherapy.

The Expanding Role of Immunotherapy

Immunotherapy harnesses the power of the body’s own immune system to fight cancer. In NSCLC, this often involves immune checkpoint inhibitors (ICIs). Recent advances, detailed in a narrative review published in August 2025, show benefit of ICIs in both the consolidation setting after chemoradiotherapy for unresectable stage III NSCLC, and in the perioperative setting for resectable stage II and III disease, used alone or in combination with chemotherapy.

The use of immunotherapy isn’t without its challenges. Metastatic NSCLC is often treated with molecularly targeted therapy and/or immunotherapy to address complex genetic mutations and immunosuppressive events that fuel malignancy. However, these therapies can have significant toxicities and may not always yield optimal clinical outcomes. Investigational treatments, such as combination therapies targeting epigenetic dysregulation of cell growth and immune modulation, are being explored.

Pharmacists as Key Navigators

Pharmacists are becoming central to the successful implementation of these evolving immunotherapy regimens. Their responsibilities extend beyond traditional dispensing and include a range of crucial functions. These include translating complex clinical trial data into practical application, assisting with treatment selection, navigating patient access to therapies, providing comprehensive patient education, managing treatment-related toxicities, and developing order sets to standardize care.

Specifically, pharmacists help ensure therapies like cemiplimab are used safely and effectively. This involves a deep understanding of the drug’s mechanism of action, potential side effects, and drug interactions. They are uniquely positioned to identify and address drug-related problems associated with both conventional and emerging NSCLC therapies.

Addressing Treatment Toxicities

Immunotherapies, while promising, can cause a range of immune-related adverse events. Pharmacists play a critical role in recognizing, managing, and preventing these toxicities. This requires close collaboration with oncologists and other healthcare professionals to monitor patients, adjust dosages, and provide supportive care. Patient education is also paramount, empowering individuals to recognize and report potential side effects promptly.

The Importance of Precision Therapy

The increasing focus on precision medicine in NSCLC means that treatment decisions are becoming increasingly individualized, based on the specific genetic and molecular characteristics of each patient’s tumor. Pharmacists contribute to this process by understanding the role of biomarkers and ensuring that patients receive the targeted therapies most likely to benefit them.

Early diagnosis, staging, and the delivery of precision therapy are essential to reduce mortality rates. While the incidence of NSCLC decreased between 2010 and 2017 due to declining smoking rates, the number of cases in younger individuals remains a concern. The prevalence of NSCLC is also substantially higher in individuals aged 65 years and older.

Future Directions

Research continues to explore new strategies to enhance the effectiveness of immunotherapy, including combination therapies and approaches to overcome resistance. Pharmacists will undoubtedly remain at the forefront of these advancements, working to translate scientific discoveries into improved outcomes for patients with NSCLC. The development of combination therapies targeting epigenetic dysregulation and immune modulation holds particular promise, as preclinical data suggest potential for reducing tumor burden in NSCLC with specific co-mutations.

Oncology pharmacists are well-equipped to provide education about side-effect profiles, monitoring parameters, and potential drug interactions, ultimately contributing to better patient care in this complex and evolving field.